NCT00036933View on ClinicalTrials.gov

Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 31, 2002

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

MUC-2-Globo H-KLH conjugate vaccine

BIOLOGICAL

QS21

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00036933 - Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer | Biotech Hunter | Biotech Hunter